



**Proteomics International**

LABORATORIES LTD

**ASX Release**  
**29 June 2020**

**ASX code: PIQ**

## **Proteomics Directors on-market purchase of shares**

Medical Technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), advises that several Directors have bought shares (cumulative \$100,000) on market over the preceding days as detailed in the ASX Appendix 3Y Notices lodged today.

In addition, Founder and Managing Director Dr Richard Lipscombe has transferred 240,000 shares from his personal name into his Superannuation Fund as detailed.

Authorised by Dr Richard Lipscombe (Managing Director) on behalf of the Board of PIQ.

ENDS

### **About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology Company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth's QEII Medical Campus.

Proteomics International's business model is centred on the commercialisation of the Company's high-speed, low cost predictive test for diabetic kidney disease, PromarkerD. The Company offsets the cash burn from R&D and product development through provision of specialist analytical services, whilst using its proprietary Promarker™ technology platform to create a pipeline of novel diagnostic tests.

### **For further information please contact:**

Dr Richard Lipscombe  
Managing Director  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Dirk van Dissel  
Corporate Advisor & Investor Relations  
T: +61 408 326 367  
E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Proteomics International Laboratories Ltd</b>
<b>ABN</b>	<b>78 169 979 971</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Richard Lipscombe
<b>Date of last notice</b>	6 April 2018

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Bjouxz Pty Ltd <The Loz Superannuation Fund>  Dr Lipscombe is beneficiary of the superannuation fund and sole director and shareholder of the trustee.
<b>Date of change</b>	24 April 2020
<b>No. of securities held prior to change</b>	<i>Direct</i> 10,074,615 fully paid ordinary shares <b>(Shares)</b>  <i>Indirect</i> 8,936,590 Shares
<b>Class</b>	(a) Shares (b) Shares
<b>Number acquired</b>	(a) 37,500 Shares. (b) 240,000 Shares.
<b>Number disposed</b>	(a) Nil. (b) 240,000 Shares.

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	(a) \$15,375 (\$0.41 per Share) (b) \$98,400 (\$0.41 per Share).
<b>No. of securities held after change</b>	<i>Direct</i> 9,872,115 Shares  <i>Indirect</i> 9,176,590 Shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	(a) On-market trade (b) Off-market transfer from direct holding to superannuation fund.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Not applicable.
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	Not applicable
<b>If prior written clearance was provided, on what date was this provided?</b>	Not applicable

---

<sup>+</sup> See chapter 19 for defined terms.

Rule 3.19A.2

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Proteomics International Laboratories Ltd
<b>ABN</b>	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Paul Edward House
<b>Date of last notice</b>	1 October 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Not applicable
<b>Date of change</b>	25 June 2020
<b>No. of securities held prior to change</b>	<p><i>Direct</i> 223,864 fully paid ordinary shares (<b>Shares</b>).</p> <p><i>Indirect</i> 375,000 Shares. 100,000 unquoted options exercisable at \$0.50 per option on or before 22 November 2021 (<b>Director A Options</b>). 100,000 unquoted options exercisable at \$0.67 per option on or before 22 November 2022 (<b>Director B Options</b>).</p>
<b>Class</b>	Shares
<b>Number acquired</b>	120,000 Shares
<b>Number disposed</b>	Nil.

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$49,200 (\$0.41 per Share)
<b>No. of securities held after change</b>	<i>Direct</i> 343,864 Shares.  <i>Indirect</i> 375,000 Shares. 100,000 Director A Options. 100,000 Director B Options.
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market trade

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Not applicable.
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

+ See chapter 19 for defined terms.

**Part 3 - +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	Not applicable
<b>If prior written clearance was provided, on what date was this provided?</b>	Not applicable

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Proteomics International Laboratories Ltd
<b>ABN</b>	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Ian Roger Moore
<b>Date of last notice</b>	22 November 2018

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect.
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Moore and Sotomi Investments Pty Ltd as trustee for the Roger Moore Family A/C  Mr Moore is a director and shareholder of the trustee and a beneficiary of the trust.
<b>Date of change</b>	25 June 2020
<b>No. of securities held prior to change</b>	<i>Direct</i> Nil.  <i>Indirect</i> 627,000 fully paid ordinary shares ( <b>Shares</b> ). 100,000 unquoted options exercisable at \$0.50 per option on or before 22 November 2021 ( <b>Director A Options</b> ). 100,000 unquoted options exercisable at \$0.67 per option on or before 22 November 2022 ( <b>Director B Options</b> ).
<b>Class</b>	Shares

+ See chapter 19 for defined terms.



**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number acquired</b>	90,000 Shares
<b>Number disposed</b>	Nil.
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$36,819 (\$0.4091 per Share)
<b>No. of securities held after change</b>	<i>Direct</i> Nil.  <i>Indirect</i> 717,000 Shares. 100,000 Director A Options. 100,000 Director B Options.
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	On-market trade

**Part 2 - Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Not applicable.
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

+ See chapter 19 for defined terms.

**Part 3 - +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

+ See chapter 19 for defined terms.